NCT07511426 2026-04-06
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Phase 1 Recruiting
Clinical Trials
22 trialsNCT06208735 2026-04-03
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Phase 1 Recruiting
NCT07487428 2026-03-23
CLL-IMPACT
Technical University of Munich
Phase NA Recruiting
NCT07422337 2026-02-25
BOOSTER
Arkansas Children's Hospital Research Institute
Recruiting
NCT07337967 2026-01-13
Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
Assiut University
Not yet recruiting
NCT02787369 2026-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT06345027 2025-12-16
CASEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT02650414 2025-12-12
CD22 Redirected Autologous T Cells for ALL
University of Pennsylvania
Phase 1 Active not recruiting
NCT03766763 2025-11-26
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT03573700 2025-11-18
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT02050347 2025-11-14
CARPASCIO
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05010564 2025-11-13
TRICAR-ALL
Baylor College of Medicine
Phase 1 Recruiting
NCT03050190 2025-09-08
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03125577 2025-09-08
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT05779930 2025-08-15
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07113132 2025-08-08
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia
Assiut University
Not yet recruiting
NCT06812715 2025-08-06
PIPOZA
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT03774654 2025-07-01
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01683279 2025-06-17
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT04515238 2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2 Active not recruiting
NCT04883749 2025-06-08
CLL-Frail
German CLL Study Group
Phase 2 Completed